WASHINGTON - The U.S. Environmental Protection Agency (EPA), the National Institute of Environmental Health Sciences National Toxicology Program (NTP) and the National Institute of Health Chemical Genomics Center (NCGC) welcome the U.S. Food and Drug Administration (FDA) to the Tox21 collaboration. The Tox21 collaboration merges federal agency resources (research, funding and testing tools) to develop ways to more effectively predict how chemicals will affect human health and the environment. The collaboration was established in 2008 to develop models that will be able to better predict how chemicals will affect humans. FDA will provide additional expertise and chemical safety information to improve current chemical testing methods.
"This collaboration is revolutionizing the current approach to chemical risk assessment by sharing expertise, capabilities and chemical information, which will lead to both a faster and deeper understanding of chemical hazards," said Dr. Paul Anastas, assistant administrator for EPA's Office of Research and Development. "Through the Tox21 collaboration, 2,000 chemicals have already been screened against dozens of biological targets and we are working to increase the number of chemicals to 10,000 by the end of the year."
There are tens of thousands of chemicals currently in commerce and current chemical testing is expensive and time consuming.
"This partnership builds upon FDA's commitment to developing new methods to evaluate the toxicity of the substances we regulate," said Dr. Janet Woodcock, director of FDA's Center for Drug Evaluation and Research.
FDA will collaborate with other Tox21 members to prioritize chemicals that need more extensive toxicological evaluation, and develop models that can better predict human response to chemicals.
EPA contributes to Tox21 through the ToxCast program and by providing chemicals and additional fast, automated tests to NCGC. ToxCast currently
|Contact: Latisha Petteway|
U.S. Environmental Protection Agency